Kalaris Therapeutics, Inc. (KLRS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kalaris Therapeutics, Inc. stock (KLRS) is currently trading at $6.12. Analyst consensus price target for KLRS is $20.33. WallStSmart rates KLRS as Sell.
- KLRS PE ratio analysis and historical PE chart
- KLRS PS ratio (Price-to-Sales) history and trend
- KLRS intrinsic value — DCF, Graham Number, EPV models
- KLRS stock price prediction 2025 2026 2027 2028 2029 2030
- KLRS fair value vs current price
- KLRS insider transactions and insider buying
- Is KLRS undervalued or overvalued?
- Kalaris Therapeutics, Inc. financial analysis — revenue, earnings, cash flow
- KLRS Piotroski F-Score and Altman Z-Score
- KLRS analyst price target and Smart Rating
Kalaris Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Kalaris Therapeutics, Inc. (KLRS) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Kalaris Therapeutics, Inc. (KLRS) Key Strengths (2)
78.86% of shares held by major funds and institutions
Trading at 1.91x book value, attractively priced
Supporting Valuation Data
Kalaris Therapeutics, Inc. (KLRS) Areas to Watch (2)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Kalaris Therapeutics, Inc. (KLRS) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 9.0/10) while 2 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.91) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap. Profitability pressure is visible in Return on Equity at -308.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -308.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KLRS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KLRS's Price-to-Sales ratio of 1196.95x sits near its historical average of 1100.65x (73th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 73% below its historical high of 4357.09x set in Dec 2020, and 2211% above its historical low of 51.8x in Dec 2024. Over the past 12 months, the PS ratio has expanded from ~974.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Kalaris Therapeutics, Inc. (KLRS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Kalaris Therapeutics, Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.04 indicates a conservative balance sheet with 42M in cash.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Kalaris Therapeutics, Inc..
Bottom Line
Kalaris Therapeutics, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kalaris Therapeutics, Inc.(KLRS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.